Alnylam Pharmaceuticals Roche Development Services Obligation — Transaction price remained flat by 0.0% to $1.06B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.2%, from $937.53M to $1.06B.
alny_segment_roche_development_services_obligation_transaction_price| Q3 '23 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $545.00M | $545.00M | $937.53M | $937.53M | $1.06B | $1.06B | $1.06B |
| QoQ Change | — | +0.0% | +72.0% | +0.0% | +13.2% | +0.0% | +0.0% |
| YoY Change | — | — | +72.0% | — | — | +13.2% | +13.2% |